Family · metabolic
Exenatide
Exendin-4 (Byetta, Bydureon brand names); GLP-1 receptor agonist; incretin mimetic
Exenatide is a synthetic version of exendin-4, a 39–amino-acid peptide originally isolated from the saliva of the Gila monster (Heloderma suspectum). It shares about 53% sequence homology with human GLP-1 but, critically, its N-terminal structure resists cleavage by dipeptidyl peptidase-4 (DPP-4), giving it a far longer functional half-life than native GLP-1. As a GLP-1 receptor agonist (incretin mimetic) it enhances glucose-dependent insulin secretion, suppresses inappropriately elevated glucagon, slows gastric emptying, and promotes satiety. The twice-daily immediate-release form (Byetta) has a short half-life of about 2.4 hours, while an extended-release microsphere formulation (Bydureon) releases the peptide gradually to allow once-weekly dosing.
Exenatide was the first GLP-1 receptor agonist approved for type 2 diabetes and is well characterized in randomized human trials. Buse et al. (Diabetes Care 2004) showed that adding twice-daily exenatide to sulfonylurea therapy over 30 weeks significantly lowered HbA1c versus placebo. The DURATION-1 trial (Drucker et al., Lancet 2008) demonstrated that the once-weekly extended-release formulation achieved greater HbA1c reduction than the twice-daily form. A review by Madsbad (Best Pract Res Clin Endocrinol Metab 2009) contextualizes exenatide and liraglutide as distinct approaches to GLP-1 receptor agonism. It is an approved prescription drug, not a compound for self-experimentation.
- Type 2 diabetes glycemic control (approved indication; twice-daily Byetta and once-weekly Bydureon)
- Weight reduction as a secondary effect studied in diabetes trials
- Investigational research in neuroscience and neurodegeneration models (exploratory)
Educational overview only — no dosing instructions in the public hub.
The most common adverse effects are gastrointestinal — nausea (often prominent early), vomiting, and diarrhea — generally improving over time. Documented serious risks include acute pancreatitis and a significant risk of hypoglycemia when combined with sulfonylureas. Because exenatide is cleared renally, it requires caution or avoidance in moderate-to-severe renal impairment, and cases of acute kidney injury have been reported. The extended-release form is associated with injection-site nodules. It is a prescription-only medicine to be used under medical supervision. 'Research-grade' exendin-4 sold outside the pharmacy chain is not a substitute and carries additional sourcing, purity, and dosing risks.
Exenatide is an approved prescription drug that should come only from a licensed pharmacy, where identity, purity, and (for Bydureon) the microsphere formulation are assured. 'Research-grade' exendin-4 of unverified composition is not equivalent to the approved medicine and carries sourcing and purity risk with no clinical oversight. Content here reflects the approved pharmaceutical product as studied in registered trials.
Approved prescription-only medication (FDA 2005; EMA authorized) for type 2 diabetes, marketed as Byetta (twice daily) and Bydureon (once weekly), requiring a physician's prescription and medical supervision. It is not an over-the-counter or research-only compound. Products sold outside this regulatory framework are not approved for human use and lack quality assurance.
Frequently asked questions
- What is Exenatide used for?
- Type 2 diabetes glycemic control (approved indication; twice-daily Byetta and once-weekly Bydureon). Weight reduction as a secondary effect studied in diabetes trials. Investigational research in neuroscience and neurodegeneration models (exploratory). Exenatide was the first GLP-1 receptor agonist approved for type 2 diabetes and is well characterized in randomized human trials. Buse et al. (Diabetes Care 2004) showed that adding twice-daily exenatide to sulfonylurea therapy over 30 weeks significantly lowered HbA1c versus placebo. The DURATION-1 trial (Drucker et al., Lancet 2008) demonstrated that the once-weekly extended-release formulation achieved greater HbA1c reduction than the twice-daily form. A review by Madsbad (Best Pract Res Clin Endocrinol Metab 2009) contextualizes exenatide and liraglutide as distinct approaches to GLP-1 receptor agonism. It is an approved prescription drug, not a compound for self-experimentation.
- Is Exenatide legal in Europe?
- Approved prescription-only medication (FDA 2005; EMA authorized) for type 2 diabetes, marketed as Byetta (twice daily) and Bydureon (once weekly), requiring a physician's prescription and medical supervision. It is not an over-the-counter or research-only compound. Products sold outside this regulatory framework are not approved for human use and lack quality assurance.
- What are the risks and side effects of Exenatide?
- The most common adverse effects are gastrointestinal — nausea (often prominent early), vomiting, and diarrhea — generally improving over time. Documented serious risks include acute pancreatitis and a significant risk of hypoglycemia when combined with sulfonylureas. Because exenatide is cleared renally, it requires caution or avoidance in moderate-to-severe renal impairment, and cases of acute kidney injury have been reported. The extended-release form is associated with injection-site nodules. It is a prescription-only medicine to be used under medical supervision. 'Research-grade' exendin-4 sold outside the pharmacy chain is not a substitute and carries additional sourcing, purity, and dosing risks.
- How is the quality of Exenatide assessed?
- Exenatide is an approved prescription drug that should come only from a licensed pharmacy, where identity, purity, and (for Bydureon) the microsphere formulation are assured. 'Research-grade' exendin-4 of unverified composition is not equivalent to the approved medicine and carries sourcing and purity risk with no clinical oversight. Content here reflects the approved pharmaceutical product as studied in registered trials.